Hong Kong Healthtech Stock News

Tencent Holdings (SEHK:700) has placed its Hy3 large language model at the center of a broader global AI initiative, expanding access across cloud platforms, open-source communities and regional partnerships in South Korea and Japan. See our latest analysis for Tencent Holdings. These AI moves come as Tencent Holdings trades at HK$481.4, with a 30-day share price return of 4.61% and a 90-day gain of 5.29%, yet a year-to-date share price decline of 22.73% and a 1-year total shareholder return...

What Laopu Gold’s New Guidance Tells You Laopu Gold (SEHK:6181) has issued new consolidated earnings guidance for the first half of 2026, flagging a sharp year over year rise in sales and revenue that investors will be watching closely. The company now expects tax inclusive sales between RMB 22,700 million and RMB 23,350 million and revenue between RMB 19,800 million and RMB 20,450 million, which it guided at roughly 60% to 66% above the prior year period. See our latest analysis for Laopu...

Even though Mediwelcome Healthcare Management & Technology Inc. ( HKG:2159 ) posted strong earnings recently, the stock...

It looks like Fourace Industries Group Holdings Limited ( HKG:1455 ) is about to go ex-dividend in the next three days...

The market rallied behind Lever Style Corporation's ( HKG:1346 ) stock, leading do a rise in the share price after its...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

While Wasion Holdings Limited ( HKG:3393 ) might not have the largest market cap around , it saw a decent share price...

As Asian markets continue to navigate a complex global landscape, investors are increasingly exploring diverse opportunities across various sectors. Penny stocks, although a term rooted in earlier market days, still capture the essence of investing in smaller or newer companies that may offer significant value. This article examines three promising Asian penny stocks with robust financial foundations and potential for growth, highlighting their ability to provide stability and opportunity in...

Why the new profit guidance matters for China Youran Dairy Group China Youran Dairy Group (SEHK:9858) told investors it expects a profit of RMB 739 million to RMB 903 million for the first half of 2026, compared with a RMB 297 million loss a year earlier. The company linked this turnaround to smaller revaluation losses on biological assets, higher culled cow prices, lower feed costs and higher milk yields, as well as improved sales volumes and gross profit from its core operations. See our...

Why Legend Holdings stock is back in focus Legend Holdings (SEHK:3396) has drawn attention after issuing preliminary earnings guidance for the first half of 2026, pointing to net profit of at least CN¥2,000 million, up at least 186% year on year. The company attributes this shift mainly to its industrial incubations and investments segment moving from loss to profit, helped by a recovery in capital markets. For investors, the guidance offers a fresh data point on how the group’s diversified...

Hong Kong Exchanges and Clearing (SEHK:388) has introduced a Five-Year China Government Bond Futures contract, giving investors a new listed tool to manage interest rate and duration exposure to Chinese Mainland government bonds. See our latest analysis for Hong Kong Exchanges and Clearing. The new China Government Bond Futures launch arrives at a time when Hong Kong Exchanges and Clearing’s share price has gained 8.26% over the past month, although the 1-year total shareholder return is...

In July 2026, Kerry Properties’ subsidiary ShengYao, together with HengJiu, secured land use rights in Shanghai’s Pudong New District for a large commercial and cultural development, committing up to RMB 5.04 billion (approximately HK$5.84 billion) through a new project company. The project is designed as a long-term, self-held investment anchored by commercial and cultural properties, underscoring Kerry Properties’ focus on recurring income and deeper exposure to Shanghai’s core...

Leadership changes at China Oilfield Services and why they matter to investors China Oilfield Services (SEHK:2883) is back in focus after shareholders approved key leadership changes at a July 29, 2026 extraordinary general meeting, drawing attention to governance and the company’s long term direction. The company elected Party Secretary and CEO Liu Jianzhong as Executive Director, Chairman and member of the Nomination Committee, while President and Deputy Party Secretary Shang Jie was...

Why Swire Pacific’s Latest Earnings Matter For Investors Swire Pacific (SEHK:19) has drawn fresh attention after reporting half year 2026 results, with sales of HK$49,446 million and net income of HK$6,769 million compared with HK$45,774 million and HK$815 million a year earlier. See our latest analysis for Swire Pacific. Swire Pacific’s recent half year 2026 earnings announcement appears to have coincided with building momentum in the stock, with the share price at HK$102.1 and a year to...

In August 2026, InnoCare Pharma announced that its BTK inhibitor orelabrutinib, combined with BCL2 inhibitor mesutoclax, received Breakthrough Therapy Designation from China’s CDE for previously treated marginal zone lymphoma, following clinical data showing a 100% overall response rate and a favorable safety profile. This recognition, alongside earlier positive Phase III results for TYK2 inhibitor fadeucravacitinib in moderate-to-severe plaque psoriasis, underscores InnoCare’s push to...

Techtronic Industries (SEHK:669) has drawn fresh attention after reporting half year 2026 earnings alongside progress on its share buyback program, giving investors new data points on sales, profitability, and capital allocation. See our latest analysis for Techtronic Industries. Techtronic Industries’ latest earnings and buyback update has coincided with strong momentum in the stock, with a 30 day share price return of 16.63% and a year to date share price return of 58.40%. The 3 year total...

Why Simcere Pharmaceutical Group Stock Is Back in Focus Simcere Pharmaceutical Group (SEHK:2096) is drawing investor attention after issuing new consolidated earnings guidance for the six months to 30 June 2026, highlighting projected year on year changes in both revenue and profit. See our latest analysis for Simcere Pharmaceutical Group. Against this earnings guidance backdrop, Simcere Pharmaceutical Group’s recent momentum has been steady, with a 30 day share price return of 2.98% and a 90...

Insiders who bought CN¥13.5m worth of Teamway International Group Holdings Limited ( HKG:1239 ) stock in the last year...

Fosun International (SEHK:656) drew fresh attention on 29 July 2026 after issuing earnings guidance that points to profit attributable to shareholders of RMB 1.5b to RMB 1.8b for the first half of 2026. See our latest analysis for Fosun International. The guidance appears to have shifted sentiment around Fosun International, with a 1-day share price return of 7.38% and a 30-day share price return of 33.60% lifting the stock to HK$5.09, even though the 1-year total shareholder return is still...

Keymed Biosciences (SEHK:2162) is back in focus after announcing that CMG901, its CLDN18.2-targeting antibody drug conjugate co developed with AstraZeneca, met primary and key secondary overall survival endpoints in a global Phase III gastric cancer trial. See our latest analysis for Keymed Biosciences. The positive CMG901 news arrives after a strong run in Keymed Biosciences, with the share price at HK$81.85 and a year to date share price return of 53.13%, while the 3 year total shareholder...

China’s decision to relax its earlier regulatory pressure on Panama following a dispute over CK Hutchison Holdings (SEHK:1) terminal concessions at the Panama Canal has refocused attention on the group’s ports and related services operations. See our latest analysis for CK Hutchison Holdings. At a share price of HK$73.25, CK Hutchison Holdings has a year to date share price return of 35.65%, while its 1 year total shareholder return of 47.68% and 3 year total shareholder return of 97.51%...

HLX43 and HLX3902 milestones put Shanghai Henlius Biotech’s pipeline in focus Shanghai Henlius Biotech (SEHK:2696) has reported fresh progress in its oncology pipeline. Regulators in China cleared a new HLX43 clinical trial in advanced solid tumours, and the first patient received HLX3902 in an early prostate cancer study. See our latest analysis for Shanghai Henlius Biotech. Shanghai Henlius Biotech’s recent HLX43 and HLX3902 updates have arrived alongside a sharp shift in sentiment, with...

The Asian markets have been experiencing a mix of geopolitical influences and economic indicators, contributing to a complex investment landscape. In such conditions, penny stocks—despite their somewhat outdated name—remain an intriguing area for investors seeking opportunities in smaller or newer companies. With strong financial foundations, these stocks can offer potential value and growth that may not be as readily available with larger firms. In this article, we explore three Asian penny...

Why Mongolian Mining Stock Is Back On Investors’ Radar Mongolian Mining (SEHK:975) drew fresh attention on 6 August 2026 after guiding for a turnaround to a consolidated net profit of about US$100 million to US$110 million for the first half of 2026. The company cited higher washed coking coal sales volume, improved average selling prices, and initial output from its gold mine as key drivers of the expected profit compared with a net loss of US$19.9 million a year earlier. See our latest...